| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Formin-2, polyploidy, hypofertility and positioning of the meiotic spindle in mouse oocytes.
|
Nat Cell Biol
|
2002
|
3.34
|
|
2
|
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
|
Blood
|
2010
|
2.08
|
|
3
|
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2012
|
1.63
|
|
4
|
Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.
|
Cancer Res
|
2008
|
1.37
|
|
5
|
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
|
Mol Cancer Ther
|
2012
|
1.33
|
|
6
|
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.
|
Cancer Chemother Pharmacol
|
2011
|
1.30
|
|
7
|
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
|
J Cell Mol Med
|
2011
|
1.22
|
|
8
|
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.
|
Mol Cancer Ther
|
2010
|
1.07
|
|
9
|
Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.
|
Gastroenterology
|
2013
|
1.07
|
|
10
|
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
|
Int J Cancer
|
2012
|
1.06
|
|
11
|
The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
|
Cancer
|
2012
|
1.04
|
|
12
|
HDM2 regulation by AURKA promotes cell survival in gastric cancer.
|
Clin Cancer Res
|
2013
|
0.94
|
|
13
|
Targeting aurora kinases in cancer treatment.
|
Curr Drug Targets
|
2011
|
0.93
|
|
14
|
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.92
|
|
15
|
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
|
Drug Metab Lett
|
2014
|
0.90
|
|
16
|
Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition.
|
J Immunol Methods
|
2010
|
0.86
|